Abiomed Inc Stock Research

ABMD Stock Price

ABMD RSI Chart

ABMD Valuation

Market Cap

17.2B

Price/Earnings (Trailing)

64.52

Price/Sales (Trailing)

16.02

EV/EBITDA

46.18

Price/Free Cashflow

79.23

ABMD Price/Sales (Trailing)

ABMD Profitability

EBT Margin

31.76%

Return on Equity

17.32%

Return on Assets

15.72%

Free Cashflow Yield

1.26%

ABMD Fundamentals

ABMD Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

7.16%

Revenue Q/Q

-4.05%

ABMD Earnings

Earnings (TTM)

266.8M

Earnings Y/Y

86.35%

Earnings Q/Q

94.55%

Price Action

Last 7 days

0.2%

Last 30 days

1.2%

Last 90 days

54.1%

Trailing 12 Months

14.7%

ABMD Financial Health

Current Ratio

7.93

ABMD Investor Care

Buy Backs (1Y)

0.58%

Diluted EPS (TTM)

5.83

Peers (Alternatives to Abiomed)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
SYK	104.1B	18.4B	2.26%	8.00%	44.16	5.64	7.84%	18.25%
ISRG	84.2B	6.2B	-4.47%	-13.27%	63.66	13.53	8.97%	-22.43%
BSX	69.1B	12.7B	0.59%	12.45%	99.06	5.45	6.68%	-32.95%
BDX	67.4B	19.0B	-5.16%	-6.78%	41.86	3.55	-0.43%	-8.78%
EW	49.8B	5.4B	2.41%	-25.12%	32.74	9.26	2.86%	1.25%
MID-CAP
SWAV	7.2T	489.7M	9.34%	31.15%	82.2K	16.8K	106.51%	2464.23%
PEN	10.2B	847.1M	-3.64%	34.52%	-5.1K	12.05	13.32%	-137.89%
GMED	5.2B	1.0B	-11.64%	-20.31%	30.19	5.09	6.76%	24.45%
IRTC	3.5B	410.9M	4.51%	-3.13%	-29.82	8.43	27.29%	-14.60%
TNDM	2.7B	801.2M	1.13%	-58.87%	-28.25	3.34	14.00%	-707.69%
SMALL-CAP
SILK	1.7B	138.6M	-15.68%	29.18%	-30.43	12.07	36.62%	-10.44%
ATEC	1.6B	350.9M	10.38%	49.06%	-10.84	4.7	44.26%	-5.42%
AVNS	1.3B	820.0M	-8.35%	-12.22%	25.89	1.59	10.13%	701.59%
CSII	828.4M	239.8M	0.30%	1.49%	-21.88	3.45	-4.74%	-31.15%

Financials for Abiomed

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	1.7%	1,074	1,056	1,032	1,003	974
S&GA Expenses	3.2%	452	438	423	414	393
R&D Expenses	0.6%	167	166	163	152	144
Costs and Expenses	2.5%	820	800	891	865	828
EBITDA	23.9%	369	298	219	217	-
EBITDA Margin	21.9%	0.34*	0.28*	0.21*	0.22*	-
Earnings Before Taxes	26.5%	341	270	191	189	212
EBT Margin	24.4%	0.32*	0.26*	0.18*	0.19*	-
Net Income	22.6%	267	218	137	133	149
Net Income Margin	20.6%	0.25*	0.21*	0.13*	0.13*	-
Free Cahsflow	-17.3%	217	263	250	246	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-0.4%	1,697	1,704	1,673	1,593	1,530
Current Assets	0.2%	1,063	1,060	976	885	871
Cash Equivalents	1.0%	182	180	133	144	242
Inventory	7.2%	102	95.00	94.00	90.00	86.00
Net PPE	-1.7%	195	198	202	197	197
Goodwill	-2.5%	73.00	75.00	77.00	77.00	78.00
Liabilities	-6.4%	157	167	170	160	145
Current Liabilities	-4.8%	134	141	138	127	114
Shareholder's Equity	0.2%	1,540	1,536	1,503	1,433	1,385
Retained Earnings	10.4%	1,125	1,019	965	904	858
Additional Paid-In Capital	2.2%	905	885	870	853	840
Accumulated Depreciation	3.9%	106	102	99.00	93.00	-
Shares Outstanding	-0.9%	45.00	46.00	46.00	46.00	45.00
Float	-	14,400	-	-	-	-

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-15.8%	251	298	285	293	282
Share Based Compensation	0.5%	54.00	53.00	53.00	54.00	55.00
Cashflow From Investing	38.2%	-162	-263	-380	-324	-250
Cashflow From Financing	-626.0%	-135	-18.67	-2.20	-1.58	6.00
Buy Backs	772.2%	253	29.00	0.00	-	-

Risks for ABMD

What is the probability of a big loss on ABMD?

80%

Probability that Abiomed stock will be more than 20% underwater in next one year

58.1%

Probability that Abiomed stock will be more than 30% underwater in next one year.

31.5%

Probability that Abiomed stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Abiomed was unfortunately bought at previous high price.

Drawdowns

Returns for ABMD

Cumulative Returns on ABMD

39.5%

10-Year Cumulative Returns

23.2%

7-Year Cumulative Returns

14.7%

5-Year Cumulative Returns

32.7%

3-Year Cumulative Returns

What are the long-term rolling returns for ABMD?

FIve years rolling returns for Abiomed.

Annualized Returns

Which funds bought or sold ABMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	sold off	-100	-217,000	-	-%
2023-03-10	BAILLIE GIFFORD & CO	reduced	-99.92	-889,365,000	1,136,580	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	sold off	-100	-1,981,000	-	-%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-98.99	-22,791,000	361,000	-%
2023-03-03	TIAA, FSB	sold off	-100	-250,000	-	-%
2023-03-01	WHITENER CAPITAL MANAGEMENT, INC.	sold off	-100	-415,000	-	-%
2023-02-28	Voya Investment Management LLC	sold off	-100	-6,959,000	-	-%
2023-02-24	National Pension Service	sold off	-100	-19,252,300	-	-%
2023-02-24	NATIXIS	sold off	-100	-2,940,000	-	-%
2023-02-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	reduced	-89.99	-8,166,000	1,501,000	0.02%

Latest Funds Activity

Are funds buying ABMD calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ABMD

No. of Funds

Abiomed News

Schedule 13G FIlings of Abiomed

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 06, 2023	baillie gifford & co	0.01%	2,991	SC 13G/A
Dec 29, 2022	millennium management llc	0.0%	0	SC 13G
Feb 09, 2022	vanguard group inc	10.64%	4,842,984	SC 13G/A
Feb 04, 2022	wellington management group llp	5.41%	2,461,221	SC 13G
Jan 18, 2022	baillie gifford & co	8.44%	3,839,980	SC 13G/A
Jan 10, 2022	blackrock inc.	10.1%	4,592,566	SC 13G/A
Feb 16, 2021	sands capital management, llc	3.27%	1,479,909	SC 13G
Feb 10, 2021	vanguard group inc	10.63%	4,801,759	SC 13G/A
Feb 10, 2021	renaissance technologies llc	4.41%	1,993,800	SC 13G/A
Jan 29, 2021	blackrock inc.	9.1%	4,127,359	SC 13G/A

ABMD Fair Value

Abiomed fair value in different scenarios

The table shows the Fair Value estimates for Abiomed for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	80.22 -	99.36 -	131.90 -	255.51 -	350.32 -
Current Inflation	74.18 -	90.52 -	117.84 -	223.06 -	303.31 -
Very High Inflation	66.71 -	79.82 -	101.20 -	185.39 -	249.11 -

Historical Abiomed Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Abiomed

View All Filings

Date Filed	Form Type	Document
Jan 06, 2023	SC 13G/A	Major Ownership Report
Jan 03, 2023	15-12G	15-12G
Dec 29, 2022	SC 13G	Major Ownership Report
Dec 27, 2022	4	Insider Trading
Dec 27, 2022	4	Insider Trading
Dec 27, 2022	4	Insider Trading
Dec 27, 2022	4	Insider Trading
Dec 27, 2022	4	Insider Trading
Dec 27, 2022	4	Insider Trading
Dec 27, 2022	4	Insider Trading

Latest Insider Trading transactions for ABMD

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-02-17	Rolle Myron L	sold (taxes)	-36,447	325	-112	-
2022-02-17	SUTTER MARTIN P	sold	-1,258,850	314	-4,000	-
2022-02-16	SUTTER MARTIN P	sold	-617,322	308	-2,000	-
2022-02-16	Weber David M	sold	-2,437,500	325	-7,500	chief operating officer
2022-02-15	SUTTER MARTIN P	sold	-607,301	303	-2,000	-
2022-02-09	Weber David M	sold	-965,311	310	-3,112	chief operating officer
2022-02-09	Weber David M	acquired	67,063	21.55	3,112	chief operating officer
2022-02-08	Weber David M	acquired	159,750	21.55	7,413	chief operating officer
2022-02-08	Weber David M	sold	-2,245,420	302	-7,413	chief operating officer
2022-02-07	Weber David M	acquired	6,465	21.55	300	chief operating officer

About Abiomed

Michael R. Minogue

www.abiomed.com

2000

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

ABMD Income Statement

2022-09-30

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 265,921	$ 248,142	$ 543,070	$ 500,727
Costs and expenses:
Cost of revenue	48,880	43,886	101,506	89,074
Research and development	42,089	41,041	82,566	78,749
Selling, general and administrative	116,958	102,779	234,954	206,263
Acquired in-process research and development	0	0	0	115,490
Costs and Expenses, Total	207,927	187,706	419,026	489,576
Other (loss) income:
Income from operations	57,994	60,436	124,044	11,151
Interest and other income, net	80,709	6,835	84,481	46,770
Income before income taxes	138,703	67,271	208,525	57,921
Income tax provision	32,570	10,318	47,838	27,493
Net income	$ 106,133	$ 56,953	$ 160,687	$ 30,428
Net income per share - basic	$ 2.34	$ 1.25	$ 3.53	$ 0.67
Weighted average shares outstanding - basic	45,372	45,437	45,475	45,374
Net income per share - diluted	$ 2.32	$ 1.24	$ 3.51	$ 0.66
Weighted average shares outstanding - diluted	45,711	45,893	45,812	45,857

ABMD Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 182,335	$ 132,818
Short-term marketable securities	638,037	625,789
Accounts receivable, net	94,475	90,608
Inventories, net	102,237	93,981
Prepaid expenses and other current assets	45,714	33,277
Total current assets	1,062,798	976,473
Long-term marketable securities	116,871	220,089
Property and equipment, net	195,157	202,490
Goodwill	72,960	76,786
Other intangibles, net	36,833	39,518
Deferred tax assets	18,881	10,552
Other assets	193,044	147,485
Total assets	1,696,544	1,673,393
Current liabilities:
Accounts payable	35,070	35,346
Accrued expenses	69,434	72,629
Deferred revenue	25,962	26,362
Other current liabilities	3,594	4,120
Total current liabilities	134,060	138,457
Other long-term liabilities	7,013	9,319
Contingent consideration	14,995	21,510
Deferred tax liabilities	689	781
Total liabilities	156,757	170,067
Commitments and contingencies (Note 16)
Stockholders' equity:
Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none
Common stock, $.01 par value 100,000 shares authorized; 48,418 and 48,258 shares issued as of September 31, 2022 and March 31, 2022, respectively 45,172 and 45,545 shares outstanding as of September 30, 2022 and March 31, 2022, respectively	452	455
Additional paid in capital	904,755	870,074
Retained earnings	1,125,199	964,512
Treasury stock at cost - 3,246 and 2,713 shares as of September 31, 2022 and March 31, 2022, respectively	(443,974)	(304,555)
Accumulated other comprehensive loss	(46,645)	(27,160)
Total stockholders' equity	1,539,787	1,503,326
Total liabilities and stockholders' equity	$ 1,696,544	$ 1,673,393